S Adachi

Summary

Affiliation: Hyogo College of Medicine
Country: Japan

Publications

  1. ncbi A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya shi, Hyogo 663 8501, Japan
    Oncol Rep 8:285-8. 2001
  2. ncbi Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo 663, Japan
    Oncol Rep 8:27-31. 2001
  3. ncbi Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya City, Hyogo, Japan
    Cancer 91:74-9. 2001
  4. ncbi Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Int J Clin Pharmacol Res 21:105-10. 2001
  5. ncbi A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Jpn J Clin Oncol 29:434-7. 1999
  6. ncbi Expression of interleukin-18 and its receptor in mouse ovary
    Y Tsuji
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Am J Reprod Immunol 46:349-57. 2001
  7. ncbi Role of IL-18 in pathogenesis of endometriosis
    H Oku
    Department of Obstetrics and Gynecology, Institute for Advanced Medical Sciences, Japan
    Hum Reprod 19:709-14. 2004
  8. ncbi Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma
    H Tsubamoto
    Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Kansai Clinical Oncology Group, Kansai, Japan
    J Clin Oncol 27:e16518. 2009
  9. ncbi Malignant epithelial tumor of unknown origin of the broad ligament
    Y Itani
    Department of Obstetrics and Gynecology, Nara Prefectural Nara Hospital, 1 30 1 Hiramatsu cho, Nara shi, Nara, 631 0847, Japan
    Arch Gynecol Obstet 267:113-6. 2002

Collaborators

Detail Information

Publications9

  1. ncbi A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya shi, Hyogo 663 8501, Japan
    Oncol Rep 8:285-8. 2001
    ..This regimen is easy to manage in heavily pretreated patients and seems to have good efficacy. To further assess the efficacy, a phase II study is needed...
  2. ncbi Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo 663, Japan
    Oncol Rep 8:27-31. 2001
    ..Our results show this to be an effective treatment regimen for epithelial ovarian cancer. Prognosis is good with this combined carboplatin/cisplatin/G-CSF therapy, especially for those patients with microscopic or no residual disease...
  3. ncbi Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya City, Hyogo, Japan
    Cancer 91:74-9. 2001
    ....
  4. ncbi Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Int J Clin Pharmacol Res 21:105-10. 2001
    ..These results show that this combination chemotherapy effected a high response rate. However, its influence on long-term survival remains to be determined...
  5. ncbi A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma
    S Adachi
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Jpn J Clin Oncol 29:434-7. 1999
    ..The treatment for ovarian clear cell adenocarcinoma has not been established. We planned a pilot study of CPT-11 and cisplatin for the treatment of ovarian clear cell adenocarcinoma...
  6. ncbi Expression of interleukin-18 and its receptor in mouse ovary
    Y Tsuji
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
    Am J Reprod Immunol 46:349-57. 2001
    ..Ovulation is thought to be an inflammation-like reaction in which many pro-inflammatory cytokines are involved. We investigated whether IL-18 is involved in the functions of ovary...
  7. ncbi Role of IL-18 in pathogenesis of endometriosis
    H Oku
    Department of Obstetrics and Gynecology, Institute for Advanced Medical Sciences, Japan
    Hum Reprod 19:709-14. 2004
    ..Interleukin (IL)-18 is a strong pleiotropic cytokine known to be involved in various immune diseases. The aim of this study is to elucidate the role of IL-18 in the pathogenesis of endometriosis...
  8. ncbi Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma
    H Tsubamoto
    Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Kansai Clinical Oncology Group, Kansai, Japan
    J Clin Oncol 27:e16518. 2009
    ..Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation...
  9. ncbi Malignant epithelial tumor of unknown origin of the broad ligament
    Y Itani
    Department of Obstetrics and Gynecology, Nara Prefectural Nara Hospital, 1 30 1 Hiramatsu cho, Nara shi, Nara, 631 0847, Japan
    Arch Gynecol Obstet 267:113-6. 2002
    ..After three courses of platinum based adjuvant chemotherapy, the patient is alive with no recurrence at 18 months postoperatively...